Cargando…

5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer

PVI 5FU gives increased response rates and reduced toxicity when compared to bolus 5FU (J Clin Oncol 1989, 425–432). PVI 5FU administration was reported to give highly variable (>1000-fold) plasma 5FU concentrations at steady state (FU Css) which correlated with toxicity (Ann Oncol 1996, 47–53);...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jodrell, D I, Stewart, M, Aird, R, Knowles, G, Bowman, A, Wall, L, Cummings, J, McLean, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363784/ https://www.ncbi.nlm.nih.gov/pubmed/11237378 http://dx.doi.org/10.1054/bjoc.2000.1664

Ejemplares similares

Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
por: Chau, I, et al.
Publicado: (2001)

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.
por: Cho, Eun Kyung, et al.
Publicado: (2002)

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
por: Allen, M J, et al.
Publicado: (2000)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
por: Crawley, C., et al.
Publicado: (1998)

Pharmacokinetic Modulation of Plasma 5‐Fluorouracil Concentrations to Potentiate the Antitumor Activity of Continuous Venous Infusion of 5‐Fluorouracil
por: Fujii, Setsuro, et al.
Publicado: (1989)

Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
por: Yamada, Y, et al.
Publicado: (2003)

Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil
por: Yeh, K-H, et al.
Publicado: (2000)

Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study
por: Humphreys, A C, et al.
Publicado: (2004)

Continuously protracted infusion of cisatracurium besilate in patients with ARDS
por: Yuan, Ziming, et al.
Publicado: (2022)

The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
por: Goldberg, J. A., et al.
Publicado: (1990)

Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma
por: Gao, Jian, et al.
Publicado: (2018)

Effects of the Plasma Concentration of 5‐Fluorouracil and the Duration of Continuous Venous Infusion of 5‐Fluorouracil with an Inhibitor of 5‐Fluorouracil Degradation on Yoshida Sarcomas in Rats
por: Fujii, Setsuro, et al.
Publicado: (1989)

Protracted Speciation under the State-Dependent Speciation and Extinction Approach
por: Hua, Xia, et al.
Publicado: (2022)

Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study
por: Matano, E, et al.
Publicado: (2000)

Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90).
por: Pierga, J. Y., et al.
Publicado: (1998)

A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
por: Kollmannsberger, C, et al.
Publicado: (2000)

402 Pharmacokinetics of Extended vs Intermittent Intravenous Infusion of Meropenem in Critically Ill Patients Receiving Continuous Veno-Venous Haemofiltration
por: Frippiat, Frédéric, et al.
Publicado: (2014)

Prolonging the Past Counteracts the Pull of the Present: Protracted Speciation Can Explain Observed Slowdowns in Diversification
por: Etienne, Rampal S., et al.
Publicado: (2012)

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study
por: Fokkema, E, et al.
Publicado: (2000)

Effects of Bolus Injection of 5-Fluorouracil on Steady-State Plasma Concentrations of 5-Fluorouracil in Japanese Patients with Advanced Colorectal Cancer
por: Tamura, Takao, et al.
Publicado: (2011)

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration
por: Jodrell, D I, et al.
Publicado: (1999)

On Protracted Gestation
por: Blake, C. Paget
Publicado: (1893)

Propofol in neonates causes a dose‐dependent profound and protracted decrease in blood pressure
por: de Kort, Ellen H. M., et al.
Publicado: (2020)

Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
por: Kalbakis, K, et al.
Publicado: (2001)

The protracted maturation of human ESC-derived interneurons
por: Tyson, Jennifer A, et al.
Publicado: (2013)

Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics
por: Hsieh, Chen-Hsi, et al.
Publicado: (2010)

Letter: Blood levels of 5-fluorouracil during intravenous infusion.
por: Kawai, M., et al.
Publicado: (1976)

Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Kinetic Analysis of 5‐Fluorouracil Action against Various Cancer Cells
por: Inaba, Makoto, et al.
Publicado: (1990)

Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic–pharmacodynamic model in gastrointestinal cancer patients
por: Arshad, Usman, et al.
Publicado: (2020)

Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19
por: Wilber, Eli, et al.
Publicado: (2022)

A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil
por: Etienne, M C, et al.
Publicado: (1999)

Steady state trials: another valid substitution of counterfactual ideal to measure causal effects
por: Iwami, Okujou, et al.
Publicado: (2012)

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin
por: Li, Zhaoyang, et al.
Publicado: (2021)

Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer
Publicado: (2001)

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes
por: Heise, Tim, et al.
Publicado: (2016)

Case of Protracted Pregnancy
por: Kelly, A. L.
Publicado: (1870)

Case of Protracted Labor
por: Harcourt, L. A.
Publicado: (1871)

Cannot write session to /tmp/vufind_sessions/sess_3dj5d0vfbrd208o2ql2fp6j7rb